低剂量卡麦角林与临床显著瓣膜病变风险:基于硬性心脏终点的队列研究
该研究基于英国东北伦敦初级保健记录,纳入646例因泌乳素瘤服用卡麦角林超过6个月的患者,匹配未暴露对照。中位累积剂量56 mg、治疗27个月、周剂量2.1 mg。卡麦角林组心脏终点发生率2.8%,对照组2.33%,匹配分析相对风险0.78(95%CI 0.41-1.48;P=0.446),未显示显著关联。结论不支持低剂量卡麦角林与临床显著瓣膜病变相关,提示可减少超声心动图监测频率。
要点
- 低剂量卡麦角林未增加瓣膜手术或心衰的硬性心脏终点风险。
- 匹配分析相对风险0.78(95%CI 0.41-1.48;P=0.446),无统计学意义。
- 研究结果支持减少对低剂量卡麦角林治疗患者的超声心动图监测频率。
核心结论
- 数据不支持低剂量卡麦角林治疗与临床显著瓣膜病变之间存在关联。
- 结果为减少监测超声心动图的频率提供了进一步证据。
研究设计与样本
- 识别646例因泌乳素瘤服用卡麦角林超过6个月的患者,按年龄、性别、种族、地点、糖尿病、高血压、缺血性心脏病和吸烟状态匹配最多5名对照。
主要发现
- 卡麦角林组18例(2.8%)和对照组62例(2.33%)达到心脏终点。
- 中位累积卡麦角林剂量56 mg(IQR 27-123),中位治疗时长27个月(IQR 15-46),中位周剂量2.1 mg。
- 单变量和多变量分析均未显示任何累积剂量/疗程的卡麦角林治疗与心脏终点发生率增加显著相关。
- 匹配分析中卡麦角林组心脏并发症相对风险0.78(95%CI 0.41-1.48;P=0.446)。
- 对6/18例受影响卡麦角林治疗患者超声心动图再分析,未发现麦角衍生物药物瓣膜病变证据。
临床怎么用
- 对于使用低剂量卡麦角林的泌乳素瘤患者,临床显著瓣膜病变风险未见增加。
- 可考虑降低常规超声心动图监测的频率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Controversy exists as to whether low-dose cabergoline is associated with clinically significant valvulopathy. Few studies examine hard cardiac endpoint data, most relying on echocardiographic findings. OBJECTIVES: To determine the prevalence of valve surgery or heart failure in patients taking cabergoline for prolactinoma against a matched nonexposed population. DESIGN: Population-based cohort study based on North East London primary care records. METHODS: Data were drawn from ~1.5 million patients' primary care records. We identified 646 patients taking cabergoline for >6 months for prolactinoma. These were matched to up to 5 control individuals matched for age, gender, ethnicity, location, diabetes, hypertension, ischemic heart disease, and smoking status. Cumulative doses/durations of treatment were calculated. Cardiac endpoints were defined as cardiac valve surgery or heart failure diagnosis (either diagnostic code or prescription code for associated medications). RESULTS: A total of 18 (2.8%) cabergoline-treated patients and 62 (2.33%) controls reached a cardiac endpoint. Median cumulative cabergoline dose was 56 mg (interquartile range [IQR] 27-123). Median treatment duration was 27 months (IQR 15-46). Median weekly dose was 2.1 mg. Neither univariate nor multivariate analysis demonstrated a significant association between cabergoline treatment at any cumulative dosage/duration and an increased incidence of cardiac endpoints. In a matched analysis, the relative risk for cardiac complications in the cabergoline-treated group was 0.78 (95% CI, 0.41-1.48; P = 0.446). Reanalysis of echocardiograms for 6/18 affected cabergoline-treated patients showed no evidence of ergot-derived drug valvulopathy. CONCLUSIONS: The data did not support an association between clinically significant valvulopathy and low-dose cabergoline treatment and provide further evidence for a reduction in frequency of surveillance echocardiography.
引用
- Stiles CE, Lloyd G, Bhattacharyya S, et al. Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints. J Clin Endocrinol Metab. 2021. PMID: 33247916. doi:10.1210/clinem/dgaa882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。